1. Home
  2. GSIT vs CABA Comparison

GSIT vs CABA Comparison

Compare GSIT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GSI Technology

GSIT

GSI Technology

HOLD

Current Price

$5.98

Market Cap

265.4M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.39

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIT
CABA
Founded
1995
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.4M
227.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GSIT
CABA
Price
$5.98
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.50
AVG Volume (30 Days)
897.1K
2.2M
Earning Date
01-29-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,024,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.00
N/A
52 Week Low
$1.62
$0.99
52 Week High
$18.15
$3.67

Technical Indicators

Market Signals
Indicator
GSIT
CABA
Relative Strength Index (RSI) 44.39 48.61
Support Level $5.26 $2.32
Resistance Level $7.25 $2.48
Average True Range (ATR) 0.49 0.14
MACD -0.05 -0.00
Stochastic Oscillator 32.01 17.50

Price Performance

Historical Comparison
GSIT
CABA

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: